- Home
- CLOV
as of 03-18-2026 3:56pm EST
$1.88
$0.05
-2.85%
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | JERSEY CITY |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $3.07 | AVG Volume (30 days): | 4.9M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | 38.03 |
| 52 Week Low/High: | $1.90 - $3.92 | Next Earning Date: | 06-01-2026 |
| Revenue: | $1,924,308,000 | Revenue Growth: | 40.34% |
| Revenue Growth (this year): | 47.8% | Revenue Growth (next year): | 12.45% |
| P/E Ratio: | -4.38 | Index: | N/A |
| Free Cash Flow: | -68977000.0 | FCF Growth: | N/A |
AI-Powered CLOV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 73.05%
73.05%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Clover Health Investments Corp. (CLOV)
Priest Brady Patrick
Sell
CEO of Home Care
CLOV Mar 4, 2026
Avg Cost/Share
$2.17
Shares
175,000
Total Value
$379,750.00
Owned After
1,998,584
SEC Form 4
Reynoso Jamie L.
Sell
CEO, Medicare Advantage
CLOV Jan 20, 2026
Avg Cost/Share
$2.58
Shares
4,597
Total Value
$11,860.26
Owned After
2,737,700
SEC Form 4
Reynoso Jamie L.
Sell
CEO, Medicare Advantage
CLOV Jan 7, 2026
Avg Cost/Share
$2.53
Shares
2,102
Total Value
$5,318.06
Owned After
2,737,700
SEC Form 4
Reynoso Jamie L.
Sell
CEO, Medicare Advantage
CLOV Dec 18, 2025
Avg Cost/Share
$2.61
Shares
4,913
Total Value
$12,822.93
Owned After
2,737,700
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Priest Brady Patrick | CLOV | CEO of Home Care | Mar 4, 2026 | Sell | $2.17 | 175,000 | $379,750.00 | 1,998,584 | |
| Reynoso Jamie L. | CLOV | CEO, Medicare Advantage | Jan 20, 2026 | Sell | $2.58 | 4,597 | $11,860.26 | 2,737,700 | |
| Reynoso Jamie L. | CLOV | CEO, Medicare Advantage | Jan 7, 2026 | Sell | $2.53 | 2,102 | $5,318.06 | 2,737,700 | |
| Reynoso Jamie L. | CLOV | CEO, Medicare Advantage | Dec 18, 2025 | Sell | $2.61 | 4,913 | $12,822.93 | 2,737,700 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 90% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 90% conf.
AI Prediction SELL
1D
-7.52%
$2.01
Act: -4.14%
5D
-12.39%
$1.90
Act: -4.60%
20D
-8.98%
$1.98
Price: $2.17 Prob +5D: 5% AUC: 1.000
0001801170-26-000050
clov-20260226FALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
CLOVER HEALTH INVESTMENTS, CORP.
(Exact name of Registrant as Specified in Its Charter)
Delaware 001-3925298-1515192 (State or Other Jurisdiction (Commission File Number)(IRS Employer
of Incorporation) Identification No.)
Not Applicable(1) Not Applicable(1)
(Address of Principal Executive Offices)(Zip Code)
Not Applicable(1) (Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Trading
Title of each class Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.0001 per shareCLOVThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
(1) We are a remote-first company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices may be directed to the email address: secretary@cloverhealth.com, or to our agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801.
Item 2.02 Results of Operations and Financial Condition. On February 26, 2026, Clover Health Investments, Corp. (the "Company") issued a press release announcing its financial results for the fourth quarter ended and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) List of Exhibits
Exhibit No.Description
99.1Press release dated February 26, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Clover Health Investments, Corp.
Date:February 26, 2026By:/s/ Peter Kuipers Name:Peter Kuipers Title:Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0001801170-25-000196
clov-20250805FALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702025-08-052025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2025
CLOVER HEALTH INVESTMENTS, CORP.
(Exact name of Registrant as Specified in Its Charter)
Delaware 001-3925298-1515192 (State or Other Jurisdiction (Commission File Number)(IRS Employer
of Incorporation) Identification No.)
Not Applicable(1) Not Applicable(1)
(Address of Principal Executive Offices)(Zip Code)
Not Applicable(1) (Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Trading
Title of each class Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.0001 per shareCLOVThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
(1) We are a remote-first company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices may be directed to the email address: secretary@cloverhealth.com, or to our agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801.
Item 2.02 Results of Operations and Financial Condition. On August 5, 2025, Clover Health Investments, Corp. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) List of Exhibits
Exhibit No.Description
99.1Press release dated August 5, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Clover Health Investments, Corp.
Date:August 5, 2025By:/s/ Peter Kuipers Name:Peter Kuipers Title:Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
2025 Q1 Q1 2025 Earnings
8-K May 6, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 6, 2025
0001801170-25-000127
clov-20250506FALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702025-05-062025-05-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2025
CLOVER HEALTH INVESTMENTS, CORP.
(Exact name of Registrant as Specified in Its Charter)
Delaware 001-3925298-1515192 (State or Other Jurisdiction (Commission File Number)(IRS Employer
of Incorporation) Identification No.)
Not Applicable(1) Not Applicable(1)
(Address of Principal Executive Offices)(Zip Code)
Not Applicable(1) (Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Trading
Title of each class Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.0001 per shareCLOVThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
(1) We are a remote-first company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices may be directed to the email address: secretary@cloverhealth.com, or to our agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801.
Item 2.02 Results of Operations and Financial Condition. On May 6, 2025, Clover Health Investments, Corp. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) List of Exhibits
Exhibit No.Description
99.1Press release dated May 6, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Clover Health Investments, Corp.
Date:May 6, 2025By:/s/ Peter Kuipers Name:Peter Kuipers Title:Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
Latest Clover Health Investments Corp. News
CLOV Breaking Stock News: Dive into CLOV Ticker-Specific Updates for Smart Investing
StockStory
1 Unprofitable Stock for Long-Term Investors and 2 We Ignore
📉
AI Sentiment
Negative
2/10
Compare CLOV vs Leading Stocks
See how CLOV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CLOV Clover Health Investments Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.